Corrigendum re "Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial" [Eur Urol 2019;76:823-30]
1 Tampere University Hospital, Tampere, Finland. Electronic address: pirkko-liisa.kellokumpu-lehtinen@tuni.fi.
2 Department of Surgery, Capio S.T. Görans Hospital, Stockholm, Sweden; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
3 Department of Radiation Sciences, Oncology, Umeå University Hospital, Umeå, Sweden.
4 Uppsala University Hospital, Uppsala, Sweden.
5 Sundsvall University Hospital, Sundsvall, Sweden.